NATICK, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that that its lead drug candidate, Selinexor (KPT-330) oral, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Help employers find you! Check out all the jobs and post your resume.
